Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Waverley Pharma Inc V.WAVE

Healthcare Biotechnology
Waverley Pharma Inc. is a biopharmaceutical company engaged in the research, development, and commercialization of human therapeutics focused on oncology. The Company is focused on the generic oncology injectable market in Europe, the United Kingdom (UK), and North America. The Company, through its subsidiaries, has entered into a license, manufacture, supply, marketing and distribution agreement with Reliance Life Sciences Private Limited, which has granted the Company an exclusive territorial license to market and sell capecitabine in the UK and Germany as well as a non-exclusive territorial license to market and sell temozolomide and erlotinib in the UK. Its generic oncology products include bortezomib and pemetrexed. Bortezomib is an injectable generic chemotherapy drug, developed for the treatment of multiple myeloma and mantle cell lymphoma. Pemetrexed is an injectable generic chemotherapy drug, developed for the treatment of non-small cell lung cancer and pleural mesothelioma.


TSXV:WAVE - Post by User

Waverley Pharma Inc > Waverley Pharma Announces Sales of its Cancer Drug in EU
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(252)
•••
Comment by moneywinner1on Aug 26, 2020 11:14am
67 Views
Post# 31455404

RE:RE:RE:RE:RE:RE:Waverley Pharma Announces Sales of its Cancer Drug in EU

RE:RE:RE:RE:RE:RE:Waverley Pharma Announces Sales of its Cancer Drug in EU Aug. 25, 2020 /CNW/ - Waverley Pharma Inc. ("Waverley Pharma" or the "Company") (TSXV: WAVE), an emerging Canadian pharmaceutical company, is pleased to announce that its wholly owned Irish subsidiary, Waverley Pharma Europe Limited, has been granted marketing authorization for Pemetrexed in Spain and Bortezomib in Italy.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities